The influence of antipsychotic medication on dopamine D2 receptor availability. A [11C] raclopride PET study - Hamlett PET-study

niversitair Medisch Centrum Groningen0 个研究点目标入组 30 人开始时间: 待定最近更新: 2024年6月18日

试验速览

暂无简介。

•* The participant understands the study and is able to provide written informed
•* Must be between the ages of 18-60
•* Sufficient command of the Dutch language
•* Must have a diagnosis of schizophrenia, schizoaffective disorder,
•schizophreniform disorder, or those classified as Other Specified Schizophrenia
•Spectrum and Other Psychotic Disorder
•* Be mentally competent, as determined by their treating physician
•* The participant has had a first episode of psychosis and uses antipsychotic
•medication at the start of the HAMLETT study
•* The participant is about to discontinue antipsychotic medication
•* Psychotic symptoms are in remission for 3-6 months
•* HAMLETT is the only medical-scientific medication study in which the patient
•participates

•* Presence of a neurological disorder
•* Visual or hearing problems that cannot be corrected
•* Participation in a scientific research study during the past year involving
•* the refusal to be informed (by notifying the participant*s physician) of
•structural brain abnormalities that could be detected during the experiment
•* MR incompatible implants in the body
•* Risk of having metal particles in the eyes
•* Tattoo*s containing red pigments that form a safety risk
•* Alcohol or substance abuse in the past 6 months
•* Insufficient knowledge of the Dutch language
•* Inability to undergo cognitive testing
•* Use of antipsychotic medication
•* dangerous or harmful behaviour (i.e. behaviour with a risk of severe physical
•injury, or actual physical injury inflicted, to self or others) occurred during
•the psychosis
•* Coercive treatment (based on a judicial ruling)

发起方